The audio-based sleep analysis company prepares for a fall 2026 clinical study completion of its at-home sleep apnea risk detection tool. Sleep Cycle recently shared that more than 150,000 people have registered interest in its upcoming sleep apnea risk detection solution ahead of its commercial launch. It features a balanced gender distribution and an overrepresentation of adults aged 45 and older, a demographic disproportionately affected by undiagnosed sleep apnea. The sleep apnea solution builds on more than a decade of experience in proprietary audio-based sleep analysis. To support regulatory submission and commercialization, Sleep Cycle recently signed an agreement with a US-based contract research organization for the validation of its sleep apnea screening.